Evaluation of neural damage in Duchenne muscular dystrophy patients

EKRAM ABDEL SALAM1, IMAN EHSAN ABDEL-MEGUID4, RANIA SHATLA2 AND SOHEIR KORRAA3

1 Department of Pediatrics, Genetic Unit, Faculty of Medicine, Cairo University; 2 Department of Pediatrics, Faculty of Medicine, Ain Shams University; 3 National Center for Radiation Research and Technology

The presence of non-progressive cognitive impairment is recognized as a common feature in a substantial proportion of patients with Duchenne muscular dystrophy (DMD). Concurrently, the amyloid beta peptide (A\textsubscript{\(\beta\)}\textsubscript{42}) protein has been associated with changes in memory and cognitive functions. Also, it has been shown that different subtypes of neural stem/progenitor cells (CD 34, CD 45, nestin) are involved in the innate repair of plasticity mechanisms by the injured brain, in which Nerve Growth Factor (NGF) acts as chemotactic agents to recruit such cells. Accordingly, the present study investigated levels of CD 34, CD 45, nestin and NGF in an attempt to investigate markers of neural regeneration in DMD. Neuro damage was assayed in terms of A\textsubscript{\(\beta\)}\textsubscript{42}. Results showed that A\textsubscript{\(\beta\)}\textsubscript{42} (21.9 ± 6.7 vs. 12.13 ± 4.5) was significantly increased among DMD patients compared to controls. NGF (165.8 ± 72 vs. 89.8 ± 35.9) and mononuclear cells expressing nestin (18.9 ± 6 vs. 9 ± 4), CD 45 (64 ± 5.4 vs. 53.3 ± 5.2) and CD34 (75 ± 6.2 vs. 60 ± 4.8) were significantly increased among DMD patients compared to controls. In conclusion cognitive function decline in DMD patients is associated with increased levels of A\textsubscript{\(\beta\)}\textsubscript{42}, which is suggested to be the cause of brain damage in such patients. The significant increase plasma NFG and in the number of mononuclear cells bearing CD34, CD45 and nestin indicates that regeneration is an ongoing process in these patients. However, this regeneration cannot counterbalance the damage induced by dystrophine mutation and increased A\textsubscript{\(\beta\)}\textsubscript{42}.

Key words: Duchenne muscular dystrophy, neural damage, cognitive function

Introduction

Duchenne muscular dystrophy (DMD) represents an X-linked recessive disorder related to mutations in the dystrophin gene which is located on chromosome Xp21.1 (1). It is one of the most common and severe forms of dystrophinopathies, characterized by progressive and disabling muscle weakness affecting approximately 1 in 3000 to 4000 male births (2). The disease is characterized by ongoing degeneration and regeneration of skeletal muscle that leads to replacement of muscle by connective tissue and fat (3).

In addition to the profound skeletal muscle lesions, DMD is associated with mild to severe cognitive deficits and poor academic achievement, which are independent from the muscular handicap or clinical environment (4). Full-scale intelligence quotient (IQ) scores of DMD patients are distributed in accordance with the assumption that the cognitive defect results from the same mutations that cause myopathy (5). In fact, about one third of DMD boys have IQ scores below 70 and display mental retardation. Deficits affect both receptive and expressive language skills, with alterations in auditory comprehension, phonological knowledge and language, and delayed acquisition of reading, which has been partly attributed to a form of developmental dyslexia, that is, dysphonetic dyslexia (5). Impaired short- and long-term memory performances are consistently reported and include defective recall, working memory, memory span, and visuo-spatial skills (5, 6-8).

Amyloid beta peptide (A\(\beta\)) is a proteolytically processed fragment of the amyloid precursor protein (APP) (9). It occurs in different length variants with peptides of 40 amino acid residues (A\(\beta\)\textsubscript{40}) and 42 amino acid residues (A\(\beta\)\textsubscript{42}), the latter is the most prevalent. The accumulation A\(\beta\) plaques is a key feature in the brains of Alzheimer Disease (AD) patients and is implicated in the disruption of normal cellular processes leading to neurodegeneration (10). A\(\beta\) is secreted into the extracellular space allowing its detection in the CSF and plasma (11). Functional studies have demonstrated that oligomeric A\(\beta\) species can impair long-term potentiation (LTP) and synaptic function in mature neurons (12). The magnitude of amyloid plaque deposition in the brain correlates poorly...
with cognitive decline, and emerging evidence suggests that Aβ oligomers may be the major culprits in this regard (13).

NGF is a neurotrophin, shown to support the survival and differentiation of neurons during brain development (14), and reduces neural degeneration (15) and promotes peripheral nerve regeneration in rats (16). Lately, it has been shown that different subtypes of neural stem/progenitor cells respond differently to traumatic brain injury, which induces their activation reflecting the induction of innate repair and plasticity mechanisms by the injured brain (17, 18), where during such process nestin and CD34 expression increases and is serum level dependent (19, 20). It was reported that CD34 cells are present in DMD patients for tissue regeneration (21). It has been demonstrated that CD45 subset comprise juvenile protective factors for the maintenance of brain microvascular health (22).

During the last two decades, the role of dystrophin in the CNS has been investigated in DMD boys and the dystrophin deficient mdx mouse (model of DMD), and have demonstrated a range of abnormalities in CNS function, from behavioral and cognitive dysfunction to alterations in the clustering of ion channels in single identified neurons (23). Accordingly, this study was conducted in order to investigate markers related to neural damage and repair in DMD patients. The study investigated levels of CD 34, CD 45 and nestin in an attempt to investigate markers of regeneration in blood of DMD patients and degeneration in terms of Aβ42 in relation to IQ.

**Subjects and methods**

Subjects were 60 boys diagnosed clinically and at the molecular level as having DMD (mean of age 8.1 ± 1.9), versus 20 age and socioeconomic matching healthy boys (mean of age 8.2 ± 2.2). Patients and controls were chosen to be free from any infection and receiving no therapeutic treatment known to increase the oxidative stress. Blood samples were drawn after their parents’ consent.

**Biochemical Investigations**

\[ \text{Aβ}_{42} \]

This was carried out using Amyloid Beta (Aβ) ELISA Kit (Millipore catalog number EZHS42 (24)).

**CD45, CD34 and Nestin Quantification**

To quantify EPCs in circulation, peripheral mononuclear cells were first isolated from the blood samples (0.5 mM EDTA). The isolated cells were labeled with the phycoerythrin (PE)-conjugated monoclonal nestin antibody and Fluorescein isothiocyanate (FITC) conjugated CD34 (Macs). The stained cells were washed with phosphate buffered saline and BSA and then analyzed by flow cytometry at the Faculty of Medicine, Cairo University (25).

**Nerve Growth Factor**

This is an enzyme-Linked immunosorbent assay, which employs an antibody specific for human for β-NGF coated on 96 well plate (26).

**IQ**

This was carried out using the Wechsler Intelligence Scale for Children third edition (WISC III): It provides scores for Verbal IQ, Performance IQ and Full Scale IQ (27).

**Results**

Results showed that Aβ42 (21.9 ± 6.7 vs. 12.13 ± 4.5) was significantly increased among DMD patients compared to controls (Table 1) and that it has a significant negative relation with IQ of the patients (Fig. 1). NGF

| Table 1. Markers of neural damage among DMD compared to controls. |
|-----------------------|---------------------|-----|-----|
|                      | DMD                | Controls | t   | P   |
| Amyloid Beta Peptide 42 | 21.9 ± 6.7         | 12.13 ± 4.5 | 4.3 | <0.001 |
| Mean of IQ            | 74.8 ± 9.3         | 95.4 ± 10 | 10.9 | <0.00001 |

| Table 2. Markers of neural regeneration among DMD compared to controls. |
|-----------------------|---------------------|-----|-----|
|                      | DMD                | Controls | t   | p   |
| Nestin                | 18.9 ± 6           | 9 ± 4  | 12.3 | <0.0001 |
| CD34                  | 75 ± 6.2           | 60 ± 4.8 | 9.1  | <0.0001 |
| CD45                  | 64 ± 5.4           | 53.3 ± 5.2 |       | <0.001 |
| -NGF (pg/ml)          | 165.8 ± 72         | 89.8 ± 35.9 | 4.6  | <0.001 |
Evaluation of neural damage in Duchenne muscular dystrophy patients

Results of the present study showed that Aβ42 was significantly higher among DMD patients compared to controls and that a significant negative correlation exist between Aβ42 and IQ of such patients. Data regarding levels of Aβ42 in DMD are null. However, it has been shown that in patients carrying mutations predicted to affect dystrophin isoforms expressed in the brain, are associated with higher risk of cognitive impairment (28) and since Aβ42 has been shown to be associated with cognitive function impairment, the present study assumed that Aβ42 levels might be increased in DMD patients compared to controls. Supporting this assumption is that: a direct relation between the deposition of insoluble Aβ42 after traumatic brain injury and the changes in brain interstitial fluid Aβ levels has been reported, where the disruption of the blood brain barrier has been shown to play an important role in the pathogenesis of epilepsy (29). Partial or generalized epilepsy has been reported in DMD (30). Also the mdx mice were shown to be susceptible to seizure among administration of convulsing drugs (31) and brain edema and severe alterations of the glial and endothelial cells have recently been demonstrated in such mice (32).

Our recent finding that Aβ 42 was significantly higher among Down syndrome (DS) patients compared to controls (20 ± 5.1 vs. 11.9 ± 3.4) (33) provides further proof that mental retardation is associated with increased levels of Aβ42 in blood and gives clue that DMD mental retardation is associated with increased levels of Aβ42. Previous studies have shown that individuals with DS have increased levels of Aβ40 and Aβ42 peptides in plasma together with increased risk for Alzheimer’s disease (AD), neuropathology and clinical dementia (34-38).

In recent years there has been a substantial increase in the understanding of the role of dystrophin in the CNS. These studies have been largely carried out on DMD boys and the dystrophin deficient mdx mouse and have demonstrated a range of abnormalities in CNS function, from behavioral and cognitive dysfunction to alterations in the clustering of ion channels in single identified neurons (39). Dystrophin is considered the central component of a scaffold of proteins expressed in a variety of tissues including the brain, where it is involved in the clustering of several membrane receptors and ion channels and in the modulation of cellular signal integration and synaptic plasticity (30). Normally, in the cerebellum, dystrophin appears to play a role in normal neuronal function or development. Two carboxy-terminal dystrophin proteins (Dp), Dp71 and Dp140, are both expressed in the brain, in addition to full-length central nervous system dystrophins, and are initiated between exons 62 and 63, and upstream from exon 44, respectively (40-42). Rearrangements in the second part of the dystrophin gene tend to be more commonly associated with cognitive impairment, and several reports described mutations in the Dp71 coding region as a factor that contributes to the severity of mental retardation (42-44). It is suggested that a lack of the Dp140 isoform is thought to play a significant role in cognitive performances in Duchenne muscular dystrophy (45, 46) and mutations involving the Dp71 region are often associated with severe cognitive impairment (47, 48).

Putative alterations of the brain vascular permeability have been suggested by some studies, which may also participate to behavioral deficits in mdx mice (31). Initial observations of mdx brains revealed severe alterations of endothelial cells with open tight junctions surrounded by swollen glial processes and enhanced vascular permeability suggesting brain blood barrier (BBB) breakdown (48). Follow-up studies suggested that this results partially from hypoxic condition leading to the activation of hypoxia inducible factor-1α contributing to both BBB opening and compensatory angiogenesis, along with changes in expression of matrix metalloproteinases, nerve and vascular growth factors (32). Hence, the hypothesis that a progressive decline in respiratory function due to muscle degeneration, could worsen the brain and cognitive impairments in advanced DMD patients through a reduction in cerebral oxygenation and BBB disruption (49).

NFG was significantly higher in blood of DMD compared to controls in the present study. Although, NFG in blood of DMD studies are scarce, a previous study has shown by means of immunohistochemistry, that regenerating muscle fibers from DMD patients consistently

Figure 1. Correlation between Aβ42 and IQ among DMD patients.
Cells expressing CD45 are regarded as muscle regener-
ly increased among DMD patients compared to controls.

A higher expression of NGF and its receptor mRNA and protein in mdx brain as compared to controls (53). NFG was markedly elevated in the male mdx mouse at 8 and 11 weeks of age (54).

In conclusion cognitive function decline in DMD pa-
tients is associated with increased levels in Aβ1-42, which is suggested to be the cause of brain damage in such pa-
tients. The significant increase plasma NFG and in the number of mononuclear cells bearing CD45, CD34, and nestin indicates that regeneration is an ongoing process in these patients. However, this regeneration cannot counterbalance the damage induced by dystrophine mutation.

References

8. Roccella M, Pace R, De Gregorio MT. Psychopathological assessment in children affected by Duchenne de Boulogne muscular dys-
mer’s disease: uncovering the secrets of secretases. Curr Opin Neu-
10. Hardy J, Selkoe D. The amyloid hypothesis of Alzheimer’s dis-
12. Walsh D, Klyubin I, Fadeeva J, et al. Naturally secreted oligom-
13. Selkoe D. Soluble oligomers of the amyloid beta-protein impair syn-


